Abionic, a Swiss developer of nanotechnology-based point-of-care (POC) diagnostics, has received the CE mark for two tests on its abioScope platform: the PSP IVD Capsule, a pancreatic stone protein (PSP) test for sepsis risk assessment and management, as well as the Ferritin IVD Capsule, a test for iron deficiency. In clinical studies, PSP has shown promise as a biomarker for identifying patients at risk for sepsis, with a sensitivity and specificity greater than current biomarkers such as C-reactive protein, procalcitonin, and white blood cell count. The abioScope measures PSP in 5 minutes at the POC. With its nanofluidic sensors, the abioScope platform also provides ferritin measurements within the same time frame to assess iron store at the POC. Studies on the Ferritin IVD Capsule test have demonstrated a sensitivity and precision of 89% and a specificity of 83%, which is comparable to results obtained by the standard reference device.